Generic Medicine Info
Concomitant use w/ CYP3A4 inducers.
Special Precautions
Patients w/ severe aortic stenosis, heart failure, hypertrophic cardiomyopathy (HCM) w/ outflow tract obstruction. Hepatic impairment. Elderly. Pregnancy and lactation. Monitoring Parameters Monitor BP carefully during the initial admin or if there is subsequent upward dose adjustment.
Adverse Reactions
Dizziness, headache, peripheral oedema, chest pain, angina exacerbation, palpitations, vasodilation, pharyngitis, sinusitis, nausea, rash.
Drug Interactions
May increase serum levels w/ CYP3A4 inhibitors. Increased levels w/ cimetidine. Increased antihypertensive effect w/ atenolol. Propranolol attenuated heart rate increase following intake of immediate-release nisoldipine. Reduced bioavailability w/ quinidine. Increased quinidine levels w/ immediate-release nisoldipine.
CIMS Class
Calcium Antagonists
ATC Classification
C08CA07 - nisoldipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on nisoldipine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in